Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens

Autor: Carolina Romero, Rodrigo Gajardo, José-María Díez

Publikováno v: Immunotherapy

Aim: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material & methods: Gamunex®-C and Flebogamma® DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10edb396a31a976e8736b92254d9ef1d
https://doi.org/10.2217/imt-2020-0095

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities

Autor: Aida Herrerias, Laura Cecilia López, Nuria Marzo, Berta Pons, Marta José, Juan I. Jorquera, Merche Faro, Maite López

Publikováno v: Biologicals : journal of the International Association of Biological Standardization. 41(6)

Studies have demonstrated that traces of activated factor XI (FXIa) present in specific brands of intravenous immunoglobulin (IVIG) concentrates may pose a thrombogenic risk.To characterize procoagulant activity during fractionation and the eliminati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae7ee75ec380234fb4a6c4f1306069e3
https://pubmed.ncbi.nlm.nih.gov/24051302

P2‐448: Peripheral amyloid‐beta mobilization with the intravenous immunoglobulin Flebogamma DIF® in Alzheimer's disease patients

Autor: Gemma Cuberas, Antonio Páez, Lluís Tárraga, Asunció Lafuente, Laura Núñez, Mar Buendía, Mercè Boada Rovira, Mireia Torres, Isabel Hernández, Isabel Roca

Publikováno v: Alzheimer's & Dementia. 7

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6800a17892b5d8ab6e1a0d4c1ba3f7a5
https://doi.org/10.1016/j.jalz.2011.05.1320

Surveillance study on the tolerability and safety of Flebogamma ^® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.

Autor: Alsina L; Allergy and Clinical Immunology Department, Hospital Sant Joan de Déu, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Passeig de Sant, Joan de Déu 2, 08950, Esplugues de Llobregat, Barcelona, Spain., Mohr A; Hematology and Oncology, OncoResearch Lerchenfeld, Lerchenfeld 14, 22081, Hamburg, Germany., Montañés M; Pharmacovigilance Department, Instituto Grifols S.A., Avinguda de la Generalitat 152-158, 08174, Sant Cugat del Vallès, Barcelona, Spain., Oliver X; Pharmacovigilance Department, Instituto Grifols S.A., Avinguda de la Generalitat 152-158, 08174, Sant Cugat del Vallès, Barcelona, Spain., Martín E; Pneumology Service, Hospital Sant Joan de Déu, Fundació Althaia. Carrer Dr. Joan Soler, s/n, 08243, Manresa, Spain., Pons J; Immunology Service, Hospital Son Espases, Carrer de Valldemossa 79, 07120, Palma de Mallorca, Spain., Drewe E; Clinical Immunology and Allergy Department, Nottingham University Hospitals - QMC Campus, Hucknall Road, Nottingham, NG5 1PB, UK., Papke J; Practice and Day Clinic for Internal Medicine and Oncology, Rosa-Luxemburg-Straße 6, 01844, Neustadt in Sachsen, Germany., Günther G; Medical Healthcare Centre for Blood and Cancer Diseases, Kurfürstenstraße 20, D-14467, Potsdam, Germany., Chee R; Clinical Immunology Department, Royal Free London NHS Foundation Trust, 17 Lyndhurst Gardens, London, NW3 5NU, UK., Gompels M; Immunology and Allergy Department, Southmead Hospital, Dorian Way, Westbury-on-Trym, Bristol, BS10 5NB, UK.

Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2017 Oct; Vol. 5 (5).